Staphylococcus-aureus-Bakteriämie – eine eigene Entität

Sebastian Weis; Achim J. Kaasch; Siegbert Rieg; Bettina Löffler; Stefan Hagel; Christina Forstner; Frank M. Brunkhorst; Mathias W. Pletz

doi:10.1055/s-0041-102453

DMW - Deutsche Medizinische Wochenschrift, Inhaltsverzeichnis

Dtsch Med Wochenschr 2015; 140(13): 982-989
DOI: 10.1055/s-0041-102453

Dossier

Multiresistente Erreger

Staphylococcus-aureus-Bakteriämie – eine eigene Entität

Staphylococcus aureus bacteremia - a distinct entity

Sebastian Weis

¹Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena

²Center for Sepsis Control and Care, Universitätsklinikum Jena

,

Achim J. Kaasch

³Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Köln

,

Siegbert Rieg

⁴Abteilung Infektiologie, Klinik für Innere Medizin II, Universitätsklinikum Freiburg

,

Bettina Löffler

⁵Institut für Medizinische Mikrobiologie, Universitätsklinikum Jena

,

Stefan Hagel

¹Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena

⁶Klinik für Innere Medizin IV, Universitätsklinikum Jena

,

Christina Forstner

¹Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena

⁷Klinische Abteilung für Infektionen und Tropenmedizin, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien

,

Frank M. Brunkhorst

⁸Zentrum für klinische Studien, Universitätsklinikum Jena

,

Mathias W. Pletz

¹Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena

› Institutsangaben

Abstract

Zusammenfassung

Bakteriämien verursacht durch Methicillin-sensible (MSSA) und Methicillin-resistente (MRSA) Staphylococcus aureus Stämme sind häufig komplizierte Infektionserkrankungen, die mit einer hohen Letalität assoziiert sind und aufgrund der Besonderheiten in Verlauf, Komplikationen und Therapie eine eigene Entität darstellen.

Diese Übersichtsarbeit befasst sich mit den aktuellen Empfehlungen zum Umgang mit MSSA und MRSA Bakteriämien und erklärt, warum der Einbezug eines klinischen Infektiologen das Überleben der Patienten verbessert und zum therapeutischen Standard gehören sollte.

Abstract

Bacteremia caused by Methicillin-sensitive (MSSA) and Methicillin-resistant (MRSA) Staphyloccus aureus strains are common and severe infections associated with high mortality rates and specific characteristics in disease course, complications and therapy. In this review, we discuss current recommendations for the diagnosis and treatment of MSSA and MRSA bloodstream infections. We also highlight why infectious disease consultation improves the treatment and outcome of patients with SAB and should be considered as a standard of care.

Schlüsselwörter

Staphylococcus aureus Bakteriämie - Infektion - MRSA - MSSA

Keywords

Staphylococcus aureus bacteraemia - infection - MRSA - MSSA

Volltext

Referenzen

Literatur
1 Bai AD, Showler A, Burry L et al. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study. J Antimicrob Chemother 2015; 70: 1539-1546
2 Bloos F, Thomas-Ruddel D, Ruddel H et al. Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: a prospective observational multi-center study. Crit Care 2014; 18: R42
3 Bodmann KF, Grabein B. Expertenkommission der PEG f. Chemotherapie. Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen Update 2010. Chemother J 2010; 19: 179-255
4 Borde JP, Kern WV. Therapie von MRSA-Infektionen. Dtsch Med Wochenschr 2012; 137: 2553-2557
5 Chan KE, Warren HS, Thadhani RI et al. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol 2012; 23: 1551-1559
6 Chang FY, MacDonald BB, Peacock Jr JE et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine 2003; 82: 322-332
7 Cockerill 3rd FR, Wilson JW, Vetter EA et al. Optimal testing parameters for blood cultures. Clin Infect Dis 2004; 38: 1724-1730
8 Coiffier G, Albert JD, Arvieux C, Guggenbuhl P. Optimizing combination rifampin therapy for staphylococcal osteoarticular infections. Joint Bone Spine 2013; 80: 11-17
9 Corona Perez-Cardona PS, Barro Ojeda V, Rodriguez Pardo D et al. Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections. J Antimicrob Chemother 2012; 67: 1749-1754
10 Cosgrove SE, Sakoulas G, Perencevich EN et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36: 53-59
11 Daver NG, Shelburne SA, Atmar RL et al. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 2007; 54: 539-544
12 Fatkenheuer G, Kaasch AJ. How deadly is meticillin-resistant Staphylococcus aureus?. Lancet Infect Dis 2014; 14: 905-907
13 Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010; 23: 14-34
14 Forstner C, Dungl C, Tobudic S et al. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence. Clin Microbiol Infect 2013; 19: E291-E297
15 Fowler Jr VG, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-665
16 Fowler Jr VG, Kong LK, Corey GR et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999; 179: 1157-1161
17 Fowler Jr VG, Olsen MK, Corey GR et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163: 2066-2072
18 Friedman ND, Kaye KS, Stout JE et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137: 791-797
19 Fuster D, Tomas X, Mayoral M et al. Prospective comparison of whole-body (18)F-FDG PET / CT and MRI of the spine in the diagnosis of haematogenous spondylodiscitis. Eur J Nucl Med Mol Imaging 2015; 42: 264-271
20 Garzoni C, Kelley WL. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol 2009; 17: 59-65
21 Habib G, Hoen B, Tornos P et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30: 2369-2413
22 Harbarth S, von Dach E, Pagani L et al. Randomized non-inferiority trial to compare trimethoprim / sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection. J Antimicrob Chemother 2015; 70: 264-272
23 Heriot G, Yeoh J, Street A et al. Echocardiography has minimal yield and may not be warranted in Staphylococcus aureus bacteremia without clinical risk factors for endocarditis. Eur J Clin Microbiol Infect Dis 2015; 34: 1231-1236
24 Holland TL, Arnold C, Fowler Jr VG. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA 2014; 312: 1330-1341
25 Holmes NE, Howden BP. What’s new in the treatment of serious MRSA infection?. Curr Opin Infect Dis 2014; 27: 471-478
26 Holmes NE, Tong SY, Davis JS, Hal SJ. Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond. Semin Respir Crit Care Med 2015; 36: 17-30
27 Honda H, Krauss MJ, Jones JC et al. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 2010; 123: 631-637
28 Jensen AG. Importance of focus identification in the treatment of Staphylococcus aureus bacteraemia. J Hosp Infect 2002; 52: 29-36
29 Jensen AG, Wachmann CH, Espersen F et al. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med 2002; 162: 25-32
30 Kaasch AJ, Barlow G, Edgeworth JD et al. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect 2014; 68: 242-251
31 Kaasch AJ, Fowler Jr VG, Rieg S et al. Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia. Clin Infect Dis 2011; 53: 1-9
32 Kaasch AJ, Rieg S, Hellmich M et al. Differential time to positivity is not predictive for central line-related Staphylococcus aureus bloodstream infection in routine clinical care. J Infect 2014; 68: 58-61
33 Kaasch AJ, Rieg S, Kuetscher J et al. Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study. Infection 2013; 41: 979-985
34 Kern WV. Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges. Curr Opin Infect Dis 2010; 23: 346-358
35 Kern WV. Umstrittene Therapieempfehlungen für die infektiöse Endokarditis. Internist 2013; 54: 1087-1088
36 Kim SH, Kim KH, Kim HB et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52: 192-197
37 Kouijzer IJ, Vos FJ, Janssen MJ et al. The value of 18F-FDG PET / CT in diagnosing infectious endocarditis. Eur J Nucl Med Mol Imaging 2013; 40: 1102-1107
38 Laupland KB, Lyytikainen O, Sogaard M et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. Clin Microbiol Infect 2013; 19: 465-471
39 Lenz R, Leal JR, Church DL et al. The distinct category of healthcare associated bloodstream infections. BMC Infect Dis 2012; 12: 85
40 Leonard SN. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic / pharmacodynamic model. PLoS One 2012; 7: e42103
41 Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-292
42 Liu GY, Essex A, Buchanan JT et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med 2005; 202: 209-215
43 Lopez-Cortes LE, Del Toro MD, Galvez-Acebal J et al. Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57: 1225-1233
44 Mitchell DH, Howden BP. Diagnosis and management of Staphylococcus aureus bacteraemia. Intern Med J 2005; 35 (Suppl. 02) S17-S24
45 Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis 2009; 48 (Suppl. 04) S231-S237
46 Palraj BR, Baddour LM, Hess EP et al. Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT): Scoring System to Guide Use of Echocardiography in the Management of Staphylococcus aureus Bacteremia. Clin Infect Dis 2015;
47 Pletz MW, Burkhardt O, Welte T. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? – Comparison of pharmacology and clinical efficacy. Eur J Med Res 2010; 15: 507-513
48 Proctor RA, von Eiff C, Kahl BC et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4: 295-305
49 Riedel S, Bourbeau P, Swartz B et al. Timing of specimen collection for blood cultures from febrile patients with bacteremia. J Clin Microbiol 2008; 46: 1381-1385
50 Rieg S, Kern WV. Die nosokomiale Staphylococcus aureus-Bakteriämie. Krankenhaushygiene up2date 2011; 6: 261-272
51 Rieg S, Peyerl-Hoffmann G, de With K et al. Mortality of S. aureus bacteremia and infectious diseases specialist consultation – a study of 521 patients in Germany. J Infect 2009; 59: 232-239
52 Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2013. Robert Koch-Institut; 2014
53 Roberts JA, Taccone FS, Udy AA et al. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011; 55: 2704-2709
54 Rubinstein E. Staphylococcus aureus bacteraemia with known sources. Int J Antimicrob Agents 2008; 32 (Suppl. 01) S18-20
55 Schmitt S, McQuillen DP, Nahass R et al. Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs. Clin Infect Dis 2014; 58: 22-28
56 Schmitz RP, Keller PM, Baier M et al. Quality of blood culture testing – a survey in intensive care units and microbiological laboratories across four European countries. Crit Care 2013; 17: R248
57 Schweizer ML, Furuno JP, Harris AD et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis 2011; 11: 279
58 Seifert H, Abele-Horn M, Fätkenheuer G et al. MiQ Blutkulturdiagnostik Sepsis, Endokarditis, Katheterinfektionen, Teil I. Müchen: Elsevier; 2007
59 Seifert H, Wisplinghoff H, Kaasch A et al. Epidemiologie, Verlauf und Prognose der Staphylococcus-aureus-Bakteriämie – Erste Ergebnisse der INSTINCT-Kohorte. Dtsch Med Wochenschr 2008; 133: 340-345
60 Sinha B, Herrmann M. Mechanism and consequences of invasion of endothelial cells by Staphylococcus aureus. Thromb Haemost 2005; 94: 266-277
61 Stratton CW, Liu C, Weeks LS. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies. Antimicrob Agents Chemother 1987; 31: 1210-1215
62 Tuchscherr L, Heitmann V, Hussain M et al. Staphylococcus aureus small-colony variants are adapted phenotypes for intracellular persistence. J Infect Dis 2010; 202: 1031-1040
63 Tuchscherr L, Medina E, Hussain M et al. Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Mol Med 2011; 3: 129-141
64 van Hal SJ, Jensen SO, Vaska VL et al. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev 2012; 25: 362-386
65 Vogel M, Schmitz RP, Hagel S et al. Impact of infectious diseases specialists consultation on the management andoutcomes of Staphylococcus aureus bacteremia – a systematic review and metaanalysis. Kopenhagen: Poster Abstract ECCMID Annual Meeting 2015
66 Vos FJ, Kullberg BJ, Sturm PD et al. Metastatic infectious disease and clinical outcome in Staphylococcus aureus and Streptococcus species bacteremia. Medicine 2012; 91: 86-94
67 Weidenmaier C, Goerke C, Wolz C. Staphylococcus aureus determinants for nasal colonization. Trends Microbiol 2012; 20: 243-250
68 Westphal N, Plicht B, Naber C. Infective endocarditis – prophylaxis, diagnostic criteria, and treatment. Dtsch Arztebl Int 2009; 106: 481-489; quiz 490
69 Yaw LK, Robinson JO, Ho KM. A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study. Lancet Infect Dis 2014; 14: 967-975